Proteomic Research on the Therapeutic Mechanism of Zhibai Dihuang Granule for Treating Hyperthyroidism Yin‐deficiency Rats
Changming Liu,Lian‐Gen Mao,Shuxu Yang,Tingting Jiang,Chong Wang,Zhongliang Chen,Hui‐Hui Tu,Zhongjie Li,Jicheng Li
DOI: https://doi.org/10.1096/fasebj.31.1_supplement.768.6
2017-01-01
Abstract:Zhibai Dihuang Granule (ZDG) is a classical traditional Chinese medicine that has been used to treat yin‐deficiency‐heat (YDH) syndrome. However, the therapeutic mechanism of ZDG is still unclear. The aim of this study was to observe the therapeutic effect and mechanism of ZDG in hyperthyroidism yin‐deficiency rats by detecting the serum proteome expression. Triiodothyronine (T3) was used to induce the hyperthyroidism yin‐deficiency model of rats, and the rats were treated daily with ZDG by gastrogavage. In the proteomics experiment, a total of 93 differentially expressed serum proteins (49 up‐regulated proteins and 44 down‐regulated proteins) were identified by iTRAQ labeling coupled with two‐dimensional liquid chromatography‐tandem mass spectrometry (2D LC‐MS/MS) analysis (fold change >1.50 or <0.60, p < 0.05) between model rats and control rats. After ZDG treatment, 16 proteins among up‐regulated proteins showed obvious downward trend, and 10 proteins among down‐regulated proteins showed obvious upward trend. Bioinformatics analysis of the proteins which returned to normal level revealed that 10 of these proteins were involved in immune response, especially in complement and coagulation cascades. After ZDG treatment, L‐selectin, C‐reactive protein (CRP), and Zinc‐alpha‐2‐glycoprotein (Azgp1) levels were significantly increased (p=0.0002, p=0.0003, p=0.0051, respectively). Therefore, we concluded that ZDG may treat YDH syndrome by regulating immune response, especially complement and coagulation cascades, and L‐selectin, CRP and Azgp1 may act as potential biomarkers to evaluate the therapeutic efficacy of ZDG. Our work provides important experimental basis to understand the mechanism of ZDG for treating YDH syndrome, and provide potential serum biomarkers for evaluating therapeutic efficacy of ZDG. Support or Funding Information This work was supported by grants from National Basic Research Program of China (No.2014CB543002), National Natural Science Foundation of China (No.81573709, No.81273882).